Disclosed herein, in part, are methods of subcutaneously administering liquid pharmaceutical formulations of furosemide to an adult patient from a prefilled cartridge using a five-hour bi-phasic delivery profile. Methods of treating congestion, edema, fluid overload, or hypertension in a patient in need thereof are also provided.

A VEGF inhibitor is used in preparation of a medicament for treating hypoxia-related diseases. The VEGF inhibitor can significantly inhibit VEGF stress expression caused by hypoxia by acting on a binding pathway of VEGF and a VEGF receptor, is used for treating hypoxia and other related diseases, can significantly improve the oxygenation index of a patient, and can alleviate the hypoxic state of lung and other organ tissues, having good therapeutic effects.

Provided herein are methods and kits for analyzing a biological sample obtained from a subject having, suspected of having, or being at risk for a disease associated with the contact activation system.

The present disclosure relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula: ##STR00001##
where R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.4′, X.sub.1, Y.sub.1, Y.sub.2, Y.sub.3, Y.sub.4, n, and m are described herein.

The present invention relates to compounds and their uses, in particular, compounds in the form of prodrugs that pro mote transport of a pharmaceutical agent to the lymphatic system and subsequently enhance release of the parent drug.

The present invention related to new humanized antanogistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same.

The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith.

An agent for elevating nitric oxide (NO) concentration comprising glutathione or a salt thereof as an active ingredient; an agent for elevating NO concentration comprising glutathione or a salt thereof as an active ingredient for preventing or ameliorating a vascular endothelial malfunction-related symptom, or dilating blood vessels or promoting blood flow by elevating NO concentration; and a method for elevating NO concentration by ingesting glutathione or a salt thereof.

The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.

Provided are novel prodrug salts of selective aquaporin inhibitors, their use as pharmaceuticals, and pharmaceutical compositions comprising them, and novel processes for their synthesis and novel intermediates for use in their synthesis. Also provided is use of a compound for the prophylaxis, treatment, and control of aquaporin-mediated conditions. Aquaporin inhibitors, e.g., inhibitors of AQP4 and/or AQP2, may be of utility in the treatment or control of diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord), hyponatremia, and excess fluid retention, as well as diseases such as epilepsy, retinal ischemia and other diseases of the eye, myocardial ischemia, myocardial ischemia/reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines.